Armistice Capital LLC Acquires New Position in Avenue Therapeutics, Inc. (NASDAQ:ATXI)

Armistice Capital LLC bought a new position in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 75,000 shares of the company’s stock, valued at approximately $262,000. Armistice Capital LLC owned 7.97% of Avenue Therapeutics as of its most recent SEC filing.

Avenue Therapeutics Trading Up 4.7 %

Shares of ATXI stock opened at $2.35 on Friday. The firm’s 50 day moving average is $2.72 and its 200 day moving average is $5.10. The stock has a market capitalization of $3.35 million, a P/E ratio of -0.30 and a beta of -0.17. Avenue Therapeutics, Inc. has a 12 month low of $2.21 and a 12 month high of $54.15.

Avenue Therapeutics (NASDAQ:ATXI) last announced its quarterly earnings results on Friday, August 9th. The company reported ($6.43) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($5.38).

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.